Find company research, competitor information, contact details & financial data for Amunix Pharmaceutical, Inc. of South San Francisco, CA. Uncover Our Platform A unified team with a singular mission. Sanofi completes acquisition of Amunix. The deal would enable Sanofi to discover and develop advanced T-cell engagers (TCE) and cytokine medicines for the treatment of cancer. The same protein-engineering technology Amunix Pharmaceuticals Inc. CEO Angie You hoped to harness for a portfolio of cancer drugs will become part of French drug company Sanofi SA as part of a . Angie You, Amunix Pharmaceuticals. Connect Biopharma is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe. Amunix Pharmaceuticals, based in South San Francisco, CA, is focused on developing masked T cell engagers and cytokines to bring the promise of these potent immune-activating biotherapeutics to . About Amunix Our novel technology and unique culture allow us to discover and develop transformative therapeutics Our clinically validated Pro-XTEN technology platform enables us to discover and develop conditionally active T cell engagers and cytokine therapies that may be transformative for cancer patients View technology Sanofi-Aventis headquarters in Paris, France. Soteria Biotherapeutics Launches with $42 Million Series A Financing Led by Roche Venture Fund and 5AM Ventures. Series B - Amunix - 2021-03-04 - Crunchbase Funding Round Profile Funding Round Series B - Amunix Summary Overview Organization Name Amunix Announced Date Mar 4, 2021 Funding Type Series B Funding Stage Early Stage Venture Money Raised $117M Lead Investors Learn More. StemoniX's microOrgan plates contain ready-to-use functional microtissues engineered from human induced pluripotent stem cells (iPSC). Amunix Pharmaceuticals's phone number is (650) 428-1800 What is Amunix Pharmaceuticals's official website? Amgen's Acquisition of Teneobio is Now Complete. Edit the message. The Frazier team really distinguish themselves by being true partners to their companies. Arjun Goyal, MD, MPHIL, MBA. south san francisco, ca - june 23, 2021 - amunix pharmaceuticals, inc. ("amunix"), an immuno-oncology company leveraging its proprietary, clinically validated pro-xten technology platform to discover and develop transformative t cell engager and cytokine therapies for patients with cancer, today announced that it has expanded its board of French healthcare company Sanofi has agreed to acquire US-based immuno-oncology company Amunix Pharmaceuticals for around $1.2bn. Amunix CEO Dec 2018 Education Angie You studied at Harvard University and Harvard University. March 4 Quick Takes: Crossovers pour into Amunix's $117M B round; plus funding for atai, BlossomHill, OnKure, Exscientia, CorVista, Blue Note and Geneos and deals for Takeda-Enzyre, ConserV-eTheRNA .day after unveiling a $73 million series A round led by Omega Funds, immuno-oncology company Amunix Pharmaceuticals Inc. . Dr. Laffitte joined DTx Pharma in 2020, bringing twenty years of pharmaceutical and biotechnology industry experience with expertise leading research teams and advancing programs from pre-clinical development through IND filings. No financial terms were disclosed. Amunix Pharmaceuticals's official website is www.amunix.com Announced Date Dec 20, 2021 Completed On Date Feb 8, 2022 Amunix Pharmaceuticals Overview Update this profile Founded 2006 Status Acquired/ Merged Employees 73 Latest Deal Type M&A Financing Rounds 6 Investments 5 General Information Description Operator of a biopharmaceutical company intended to discover, design and develop novel biologics, protein and peptide therapeutics. LinkedIn. Amunix Pharmaceuticals, based in Mountain View, CA, is a privately held drug discovery and development company with two proprietary technologies, XTEN and ProTIA, that enable the rapid generation of protein therapeutics that are engineered to be fit for purpose. south san francisco, calif., june 23, 2021 (globe newswire) -- amunix pharmaceuticals, inc. ("amunix"), an immuno-oncology company leveraging its proprietary, clinically validated pro-xten. Silicon Valley-based Amunix Pharmaceuticals Inc, a biopharmaceutical company, has raised $73 million in Series A financing. Pharmaceutical. The top amount of exits for fund were in 2019. Amunix Pharmaceuticals is an immuno-oncology company focused on designing and developing masked T cell engagers and cytokines to bring the promise of these potent immune-activating biotherapeutics . The Company designs and develops platform to improve immune stimulators for curing patient diagnosed with tumor cancers. The venture was found in North America in United States. 21 December 2021. Mar 5, 2021 For most of its 15 years, Amunix Pharmaceuticals Inc. lived off the protein engineering legacy of founder Volker Schellenberger, watching licensing deals for its protein-engineering. With operations and expertise in China, the United States and Australia and clinical development activities in those . Home; PARIS (Reuters) - Drugmaker Sanofi SA will buy Amunix Pharmaceuticals Inc for an upfront payment of about $1 billion, marking the latest acquisition by the French drugmaker in the U.S. biotech. . Sanofi has agreed to acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company. Additionally, Angie You has had 2 past jobs including Chief Business & Strategy Officer & Head of Commercial at Sierra Oncology. Amunix Pharmaceuticals, Inc. operates as a biotechnology company. Acquiring Organization: Sanofi Sanofi is engaged in the research, development, manufacturing, and marketing of innovative therapeutic solutions. January 3, 2019 by Talent4Boards Team. Designed to enable high-throughput human drug screening without the need for drugs to enter a human body, our microOrgans offer significant cost and time savings for our partners. Co-Founder and Managing Director Vida Ventures. PARIS - December 21, 2021 - Sanofi announced today that it has entered into an agreement to acquire Amunix Pharmaceuticals, Inc., an immuno-oncology company leveraging its proprietary, clinically validated XTEN and innovative universal protease-releasable masking technology platform, Pro-XTEN TM, to discover and develop transformative T . Nov 12, 2020. Join to connect Amunix Pharmaceuticals. French drug company Sanofi SA announced plans Tuesday to acquire Amunix Pharmaceuticals Inc. for as much as $1.2 billion. Nearly two months after inking a licensing deal worth up to $1.5 billion with Swiss pharma giant Roche, Amunix Pharmaceuticals secured $73 million in an oversubscribed Series A financing round that will support the development of its pipeline of novel T cell engagers (XPATs) and cytokines (XPACs).. California-based Amunix said it will combine the $73 million from the financing round with the . (Credit: Tangopaso/Wikipedia.) Number of Current Jobs 1 Number of Past Jobs 2 Angie You is the CEO at Amunix. The round was led by Boston-based Omega funds, with active participation from existing investor Frazier Healthcare Partners, and new investors Polaris Partners, Redmile Group, Longitude . Chairman of the Board, Centessa Pharmaceuticals Co-Founder & Partner, Medicxi. June 02, 2022. This is designed to be a 'bite-sized' education campaign to help explain the role that proteinuria plays in Focal Segmental Glomerulosclerosis (FSGS) and its use as a clinically meaningful endpoint to assess investigational kidney disease therapeutics, like GFB-887, our lead precision medicine candidate. Associate Director, Global Project Manager at Amunix Pharmaceuticals, a Sanofi Company Greater Madison Area 500+ connections. Under the terms of the agreement, Sanofi will acquire Amunix Pharmaceuticals for an upfront payment of approximately $1 billion and up to $225 million upon achievement of certain future development milestones. May 17, 2021. Amunix has invented XTEN, a validated therapeutic half-life extension technology. south san francisco, calif., jan. 26, 2021 (globe newswire) -- amunix pharmaceuticals, inc. ("amunix"), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent. MOUNTAIN VIEW, CA; March 4, 2020 - Amunix Pharmaceuticals, Inc. ("Amunix"), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing. August 11, 2022. For 60 years, sequence and structure has been the primary lens to understand protein function. News Jul 18, 2022. biopharma-reporter.com Eden Biologics finalizes sale of CDMO assets to Bora . ALBRIOZA (also known as AMX0035) is an oral fixed-dose combination therapy that may reduce neuronal cell death in people living with ALS, either as a stand-alone therapy or when added to existing . The company's goal is to leverage its protein engineering platform and know . ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences. Eikon Therapeutics is a drug discovery and development company that leverages super-resolution microscopy as well as the latest advances in biology, chemistry, engineering, and automation toward the goal of discovering and inventing innovative therapies that will improve and extend life. The company is focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers. SOUTH SAN FRANCISCO, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. ("Amunix"), an immuno-oncology company leveraging its proprietary, clinically validated Pro-XTEN technology platform to discover and develop transformative T cell engager and cytokine therapies for patients with cancer, today announced that it has expanded its board of directors with the appointment . Amunix Pharmaceuticals's headquarters are in 2 Tower Pl, #1100, South San Francisco, California, 94080, United States What is Amunix Pharmaceuticals's phone number? The transaction is expected to be modestly dilutive to Sanofi's EPS in 2022. As part of the announced deal, Sanofi (NASDAQ: SNY) would pay about $1. Mary Lynne Hedley, PhD. March 5, 2020 Solid tumour-focused Amunix raises $73m in Series A round California-based Amunix Pharmaceuticals has raised $73m in the Series A financing round. Sanofi will buy Amunix for about $1 billion up front and up to $225 million if certain future development milestones are met, according to the terms of the agreement. University of Wisconsin . paris - december 21, 2021 - sanofi announced today that it has entered into an agreement to acquire amunix pharmaceuticals, inc., an immuno-oncology company leveraging its proprietary, clinically validated xten and innovative universal protease-releasable masking technology platform, pro-xten tm, to discover and develop transformative t-cell Soteria Biotherapeutics Announces Scientific Advisory Board Viking Global Investors appeared to be the Corporate Investor, which was created in 1999. Biopharma. See more info on crunchbase. Contact. Amunix Pharmaceuticals a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers announced it raised an oversubscribed $73 million Series A financing. Amunix Pharmaceuticals, Inc. ("Amunix"), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing. and Harvard. The VP/SVP of Research will report directly to Darcy Mootz, Ph.D, the Head of Amunix. Senior Fellow and Strategic Advisor The Broad Institute of M.I.T. Dr. Laffitte was previously Vice President, Biology at Inception Therapeutics where he managed the research . We are committed to delivering solutions for patients who may have once thought there was no treatment option for their disease. Angie You works as the CEO at Amunix Pharmaceutical. Prior to joining Amunix, Dr. You served as Chief Business & Strategy Officer and Head of Commercial at Sierra Oncology (NASDAQ: SRRA), a publicly listed hematology and oncology drug development company, where she helped the company through a successful initial public offering that raised over $150 million. Summary. - USA, CA - Amunix Pharmaceuticals Inc., a biopharmaceutical company focused on the discovery and development of novel protein therapeutics, today announced the appointment of Angie You, Ph.D., as Chief Executive Officer, and Rich Heyman, Ph.D., as Chairman of the Board of Directors. Click through each fact! Amylyx is proud to announce that Health Canada has approved ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine), with conditions, for the treatment of amyotrophic lateral sclerosis (ALS). Get the latest business insights from Dun & Bradstreet. Get the most out of Crunchbase . For more information about Frazier Healthcare Partners, visit the company's website at. Amunix Amunix is a biopharmaceutical company intended to discover, design, and develop novel biologics, protein, and peptide therapeutics. ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update. Chimerix's mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. San Diego, California, United States 101-250 Post-IPO Equity Public www.gossamerbio.com 10,307 Highlights Stock Symbol NASDAQ:GOSS Acquisitions 1 Total Funding Amount $600M Contacts 131 Employee Profiles 6 Try Pro . paris - december 21, 2021 - sanofi announced today that it has entered into an agreement to acquire amunix pharmaceuticals, inc., an immuno-oncology company leveraging its proprietary, clinically. About Chimerix. ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes August 15, 2022 The richness of the cellular context gives us a unique approach to unlock key cancer drivers that . The funding was led by Boston-based Omega Funds; other investors include Frazier Healthcare Partners, Longitude Capital, Venrock and Polaris Partners. The main department of described Corporate Investor is located in the Greenwich.
Nike Flat Front Golf Shorts, Gene Editing Conference 2022, Hot Water Storage Tank With Heat Exchanger, 3/8 Stainless Steel U Bolts, Best Sunscreen Recommended By Dermatologists, Kerotin Shampoo And Conditioner, Parlor Guitar Vs Dreadnought,